Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Veklury Expands Label for Mild COVID-19
March 22, 2022
- MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17
March 18, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
- MHLW to Ponder Integration of Drug Supply Info with Industry Input: Minister
March 17, 2022
- LDP Project Team to Discuss Fourth COVID Shot
March 17, 2022
- Japan to Secure Extra 3 Million Doses of COVID Drugs, 145 Million Vaccine Shots Too: PM
March 17, 2022
- Economic Security Bill to Enter Diet Deliberations on March 17
March 17, 2022
- Japan Approves Array of Fertility Treatments ahead of Coverage Rollout
March 16, 2022
- MHLW Orders Label Revisions for Brilinta, Ofev, Stocrin
March 16, 2022
- Japan to Ponder Drug Pricing that Ensures Domestic API Production: PM
March 15, 2022
- Japan to Start Booster Program for Ages 12-17 from as Early as April
March 14, 2022
- Japan to Decide on 4th COVID Shot Based on Science, Overseas Reponses: Minister
March 11, 2022
- MHLW to Conduct Follow-Up Survey on Pediatric COVID Vaccinations
March 10, 2022
- Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
March 10, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- MHLW Drafts Guidelines for Evaluating SaMD Used for Behavioral Modification
March 9, 2022
- MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
- MHLW to Fund Development of Kowa’s Ivermectin for COVID-19
March 7, 2022
- MHLW Panel Confirms Positive Cost-Benefit Profile, Efficacy for 9-Valent HPV Vaccine for NIP Inclusion
March 7, 2022
- MHLW Panel Endorses Takeda’s HAE Med and More, Drops AZ’s Asthma Drug
March 4, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…